GLP-1 Receptor Agonists for Weight Loss 2026: FDA-Approved Options, Cost & Prescription Guide

Verified April 2026: GLP-1 receptor agonists for weight loss require a BMI of 30+ (or 27+ with a comorbidity like type 2 diabetes) and produce 14.9% body weight loss for semaglutide (STEP-1 trial) and 20.9% for tirzepatide (SURMOUNT-1 trial) over 68-72 weeks. Among the lowest-cost legal paths are Yucca Health at $146/month (compounded semaglutide), Enhance MD from $99 first month ($280/month after, compounded tirzepatide), and Strut Health at $149/month for oral compounded semaglutide. Brand-name option: Hers Wegovy at $149/month via the 2026 Novo Nordisk partnership (cheapest brand Wegovy on the market).

Quick answer by priority:

• •Low-cost all-in: Yucca Health $146/mo or Strut Health $149/mo oral
• •Maximum weight loss: Tirzepatide via Enhance MD compounded from $99 first month or Sprout Health compounded from $199 first month (dedicated care coordinator)
• •FDA-approved brand only: Hers Wegovy $149/mo (Novo partnership, cheapest brand Wegovy on the market)
• •Non-injectable tirzepatide: Embody oral gum $149 first month, dissolvable tirzepatide, no injection, no fasting required. $299/mo ongoing.
• •Pill (no injection): Foundayo from $149/mo (orforglipron, 12.4% loss) or oral Wegovy $1,349/mo (16.6% loss)
• •Medicare: Coverage starts July 2026 at $50/mo copay. See Medicare Part D guide.
• •Undecided: Take the 60-second match quiz.

This guide covers eligibility, medication selection, cost breakdown by insurance status, side effects, and the full 5-step telehealth process, all based on FDA prescribing information, published trial data, and verified pricing from all 48 telehealth providers we track.

How to Get GLP-1 Agonists for Weight Loss in 2026, 5 Steps

Here's the exact process for getting GLP-1 agonists for weight loss in 2026. The whole thing takes 5-10 minutes online and medication ships within 2-7 days.

• •Step 1: Check if you qualify. FDA eligibility requires a BMI of 30 or higher (obesity), or a BMI of 27 or higher with at least one weight-related condition: type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or fatty liver. Use our free eligibility checker to run the numbers in 30 seconds.
• •Step 2: Choose a medication type. The main options are brand-name injectables (Wegovy, Zepbound) at $299-$449/mo self-pay, compounded injectables at $99-$250/mo cash-pay, or oral pills (Rybelsus, Wegovy pill, Foundayo) at $149-$649/mo. Read our brand vs compounded guide to understand the tradeoffs.
• •Step 3: Pick a telehealth provider. 40 licensed GLP-1 providers operate in all 50 states. Among the lowest-cost all-in options are Enhance MD ($49 first month compounded semaglutide, $99 first month compounded tirzepatide), Strut Health ($149/mo oral semaglutide), and Hers ($149/mo brand-name Wegovy via Novo Nordisk). See our full cheapest ranking or take the match quiz.
• •Step 4: Complete the online medical intake. Every reputable provider requires a health questionnaire covering your medical history, current medications, and weight loss goals. Most accept async intake (no video call needed) and approve within 24-72 hours. Some providers like Shed ship within 2-3 days of signup.
• •Step 5: Start treatment. Medication ships directly to your home. You'll self-inject once weekly (for injectables) or take a daily pill (for orals) at the lowest starting dose. Dose escalation happens over 16-20 weeks. Read our first month on GLP-1 guide for a week-by-week timeline.

How Do GLP-1 Medications Work?

GLP-1 receptor agonists are synthetic versions of a gut hormone called glucagon-like peptide-1 (GLP-1) that your body naturally produces after eating. They work through three distinct mechanisms:

• •Appetite suppression: They act on GLP-1 receptors in the hypothalamus, your brain's satiety center, reducing hunger signals. They also lower ghrelin (the "hunger hormone") and increase fullness hormones like peptide YY.
• •Delayed gastric emptying: They slow how quickly food leaves your stomach, keeping you feeling full longer after meals.
• •Glucose regulation: They stimulate insulin release and suppress glucagon from the pancreas, which is why they were originally developed for Type 2 diabetes.

Tirzepatide (sold as Zepbound and Mounjaro) takes this further, it's a dual GIP/GLP-1 receptor agonist, activating two different incretin receptors simultaneously. This dual mechanism may explain why tirzepatide consistently shows higher weight loss numbers in clinical trials.

Which GLP-1 Medications Are FDA-Approved for Weight Loss?

As of April 2026, the following GLP-1 receptor agonists are FDA-approved specifically for chronic weight management:

Ozempic and Mounjaro are FDA-approved only for Type 2 diabetes, not weight loss. However, doctors can and do prescribe them off-label for weight management. If your provider prescribes Ozempic instead of Wegovy, this is legal but your insurance may not cover it for weight loss.

How Much Weight Can You Lose on GLP-1 Medications?

The weight loss numbers from major clinical trials are significant. These are averages from large, placebo-controlled studies published in peer-reviewed journals like the New England Journal of Medicine.

In the STEP 1 trial, about 86% of participants on semaglutide 2.4mg achieved at least 5% weight loss, and roughly 51-64% lost 15% or more. In SURMOUNT-1, 96% of participants on the 15mg tirzepatide dose achieved at least 5% weight loss, and 36% lost more than 25% of their body weight.

The head-to-head SURMOUNT-5 trial (published May 2025 in NEJM) showed tirzepatide produced significantly greater weight loss than semaglutide at maximum doses, 20.2% vs 13.7%. Tirzepatide also had a lower rate of GI-related discontinuation (2.7% vs 5.6%).

What Are the Side Effects?

GI side effects are the most common issue. From the Wegovy prescribing information and STEP trials:

The key insight: 98.1% of GI side effects were mild-to-moderate. Only 4.1% of Wegovy patients reported severe GI reactions. Side effects are worst during dose escalation (the first few weeks at each new dose level) and generally decrease over time. Both medications use gradual dose-titration schedules specifically to minimize these effects.

Who Qualifies for GLP-1 Medications?

The FDA-approved eligibility criteria for GLP-1 weight loss medications:

• •BMI of 30 or higher (obesity), OR
• •BMI of 27 or higher (overweight) with at least one weight-related health condition

Qualifying comorbidities include Type 2 diabetes, hypertension, high cholesterol, cardiovascular disease, sleep apnea, non-alcoholic fatty liver disease (NAFLD), and PCOS, among others.

Wegovy is also approved for patients aged 12 and older with obesity. Insurance companies may apply stricter criteria, some require a BMI of 35+, documented failed diet/exercise attempts, or prior authorization.

How Do You Choose a GLP-1 Provider?

Most GLP-1 prescriptions in 2026 come through telehealth platforms. When evaluating providers, consider:

• •Medication options: Do they offer both brand-name and compounded? Brand-only? Only compounded?
• •Clinical support: Is there ongoing physician oversight, or just an initial consultation?
• •Insurance: Do they accept your insurance, or is it cash-pay only?
• •Total cost: Monthly medication cost plus any consultation, lab work, or membership fees.
• •Dose titration: Do they follow standard dose escalation schedules?

We independently evaluate and rank 48 telehealth GLP-1 providers on our homepage. Check our rankings or take our quiz to find the best match for your budget and preferences.